Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928299 | 1.00 | CHRM4 (0.38) | CHRM4CHRM5CHRM1CHRM3CYP2D6 | |
| SCHEMBL23175194 | 0.88 | SMN1; SMN2 (0.46) | CHRM1CHRM3CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL3749371 | 0.88 | SMN1; SMN2 (0.46) | CHRM1CHRM3CYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL1928295 | 0.87 | CYP2D6 (0.46) | CHRM4CHRM5CHRM1CHRM3CYP2D6 | |
| SCHEMBL16382667 | 0.82 | CHRM4 (0.32) | CHRM4CHRM3HRH3 | |
| SCHEMBL8487018 | 0.78 | HRH3 (0.32) | HRH3 | |
| SCHEMBL8540595 | 0.78 | TP53 (0.42) | CYP2D6HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL9918150 | 0.78 | HRH3 (0.32) | HRH3 | |
| SCHEMBL8540599 | 0.78 | TP53 (0.42) | CYP2D6HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL8540600 | 0.78 | TP53 (0.42) | CYP2D6HRH3SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633227-B2 | Synthesis and novel salt forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine | TARGACEPT, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8153821-B2 | Compounds | TARGACEPT, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120015983-A1 | Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine | TARGACEPT, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110269975-A1 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-7615648-B2 | Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015983-A1 | Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, REN, SRMS | CHRM4 3192/4885CHRM5 2471/4885CHRM1 4422/4885 |
| US-20110269975-A1 | NOVEL COMPOUNDS | CHRNB2, CHRNA2, CHRNA5 | CHRM4 16/4885CHRM5 17/4885CHRM1 21/4885 |
| US-20080004330-A1 | Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake | SLC6A2, TPH1, SLC6A3 | CHRM4 140/4885CHRM5 76/4885CHRM1 36/4885 |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | CHRM1, CHRM2, CHRM5 | CHRM4 4/4885CHRM5 3/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.